PSMD1 and COVID-19: In 11 (24.4%) rituximab-exposed and 18 (20.0%) rituximab-naïve subjects, the attenuated humoral immune responses to COVID-19 manifested as the production of SARS-CoV-2 binding antibodies without viral neutralizing capacity (i.e., tested positive for SARS-CoV-2-specific S1 RBD IgG but negative for neutralizing antibody by sVNT).